MDA Opens 2027 Conference Registration in Orlando

Scientists racing to cure muscular dystrophy and related diseases now have their tickets to share the latest breakthroughs at the world's leading neuromuscular conference.

The Muscular Dystrophy Association just opened registration for its 2027 Clinical & Scientific Conference, happening March 21-24 in Orlando, Florida. The event brings together researchers, doctors, advocates, and families to discuss advances in treating muscular dystrophy, ALS, and other neuromuscular conditions.

"Neuromuscular research is entering a period of unprecedented acceleration," said Sharon Hesterlee, the MDA's president and CEO. She points to advances in genetics, data science, and emerging technologies pushing treatments from lab discoveries to actual patient care faster than ever before.

The conference takes place at Rosen Shingle Creek, where hundreds of minds will collaborate on the science that matters most. Researchers can submit their latest findings until mid-December, with room for late-breaking discoveries in early 2027.

What makes this gathering special goes beyond PowerPoint presentations and research posters. Barry Byrne, the MDA's chief medical advisor, notes that breakthrough ideas often emerge from hallway conversations between scientists who might never otherwise meet.

This year brings something new to the table. A dedicated NeuroMuscular Advocacy Collaborative and Patient Advocacy Pavilion will unite advocacy organizations to align their goals and strengthen their collective voice.

"That collaboration ensures that as science advances, it translates more quickly into access to treatments, stronger caregiver support, and policies that enable independence," explained Paul Melmeyer, the MDA's executive vice president for public policy and advocacy.

The conference welcomes everyone, not just the lab coat crowd. Families registered with the MDA can apply to attend virtually at no cost, watching presentations and participating in discussions from home.

The timing couldn't be better. Artificial intelligence and precision medicine are revolutionizing how researchers understand and treat progressive diseases. Angela Lek, the MDA's chief research officer, believes this convergence of science, care, and advocacy arrives at a critical moment for the field.

The Ripple Effect

Beyond the conference walls, the MDA's impact ripples through the neuromuscular community year-round. The organization currently funds more than 130 active research grants pushing the boundaries of what's possible. Their MDA Care Center Network coordinates specialty centers nationwide, ensuring people with muscular dystrophy receive exceptional care close to home.

Early-bird registration rates remain available through December, giving researchers and advocates time to plan their trip to Florida.

The conversations that happen in Orlando next March could become the therapies that change lives in the years ahead.